| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FCER1A |
| Uniprot No | P12319 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-257aa |
| 氨基酸序列 | MAPAMESPTLLCVALLFFAPDGVLAVPQKPKVSLNPPWNRIFKGENVTLT CNGNNFFEVSSTKWFHNGSLSEETNSSLNIVNAKFEDSGEYKCQHQQVNE SEPVYLEVFSDWLLLQASAEVVMEGQPLFLRCHGWRNWDVYKVIYYKDGE ALKYWYENHNISITNATVEDSGTYYCTGKVWQLDYESEPLNITVIKAPRE KYWLQFFIPLLVVILFAVDTGLFISTQQQVTFLLKIKRTRKGFRLLNPHP KPNPKNN |
| 预测分子量 | 54 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **FCER1A重组蛋白** 的3篇参考文献示例(注：文献为示例性内容，非真实发表论文)：
---
1. **文献名称**：*Expression and Functional Characterization of Recombinant Human FCER1A in Mammalian Cells*
**作者**：Smith A, et al.
**摘要**：本研究成功在HEK293细胞中表达了重组人源FCER1A蛋白，并通过亲和层析纯化获得高纯度产物。功能实验证实，重组FCER1A可特异性结合IgE，并激活下游肥大细胞信号通路，为过敏机制研究提供了工具。
2. **文献名称**：*Structural Insights into FCER1A-IgE Interaction via Recombinant Protein Crystallography*
**作者**：Zhang Y, et al.
**摘要**：通过大肠杆菌系统表达并纯化FCER1A胞外结构域重组蛋白，利用X射线晶体学解析其与IgE结合的复合物结构。研究揭示了FCER1A关键氨基酸残基在识别IgE中的作用，为靶向药物设计奠定基础。
3. **文献名称**：*Development of a FCER1A-Based Biosensor for High-Throughput Screening of Anti-Allergic Compounds*
**作者**：Lee H, et al.
**摘要**：将重组FCER1A蛋白固定于生物传感器芯片，建立了一种检测IgE结合抑制剂的高通量平台。该技术筛选出多种小分子抑制剂，显著阻断过敏反应中肥大细胞的活化。
---
**备注**：以上文献为示例，实际研究可参考PubMed或SciFinder中关键词“FCER1A recombinant protein”或“IgE receptor alpha subunit expression”获取最新进展。
FCER1A, the alpha subunit of the high-affinity immunoglobulin epsilon receptor (FcεRI), is a critical component in IgE-mediated allergic responses. This transmembrane protein, encoded by the FCER1A gene, forms part of the FcεRI complex expressed primarily on mast cells and basophils. It binds IgE antibodies with high specificity, triggering cell activation and subsequent release of inflammatory mediators like histamine upon allergen exposure. Dysregulation of this pathway underlies allergic disorders such as asthma, atopic dermatitis, and anaphylaxis.
Recombinant FCER1A protein is produced through genetic engineering, typically using mammalian or insect expression systems to ensure proper glycosylation and structural fidelity. The purified protein retains IgE-binding capacity, making it valuable for studying IgE-receptor interactions, signal transduction mechanisms, and mast cell activation processes. Researchers utilize it in assays to screen therapeutic candidates, including monoclonal antibodies or small molecules targeting allergic pathways. In diagnostics, recombinant FCER1A serves as a tool for detecting allergen-specific IgE in serum or developing biosensors for hypersensitivity testing. Its structural characterization has also advanced our understanding of receptor assembly, particularly its interaction with FcεRI’s beta and gamma subunits. Recent applications extend to personalized medicine, where recombinant FCER1A helps identify patients with genetic variants affecting receptor function or drug response. As IgE-mediated diseases remain a global health burden, this recombinant protein continues to support both basic research and translational efforts to develop targeted anti-allergic therapies.
×
